Navigation Links
Roche Submits Application for Clearance of Chlamydia and Gonorrhoeae Test
Date:5/6/2011

PLEASANTON, Calif., May 6, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has filed for FDA clearance of its Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) tests.

When cleared this standardized and fully automated test will help physicians detect and subsequently treat patients with the disease. Clinical trial data will be presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID, May 7-13, Milan, Italy) demonstrating the effectiveness of the assay using multiple sample types. The test is suitable for use in a broad range of settings and laboratories. Roche was the first company to offer a Polymerase Chain Reaction (PCR) based CT/NG test. This latest offering builds on that legacy while introducing novel features that meet customer needs.

"We are pleased to submit for review this innovative test that will address a key medical need," said Paul Brown, Ph.D., Head of Roche Molecular Diagnostics. "With this test Roche will expand the menu on the recently approved cobas 4800 platform currently in use in the US for HPV testing and so continue to improve the workflow for laboratories."

About ChlamydiaChlamydia is the most common bacterial Sexually Transmitted Disease (STD) with the highest prevalence among youth. Routine screening for chlamydial infection in young women has been demonstrated to reduce infection rates and the long-term consequences of untreated disease, as well as lowering the cost of this STD to society.  The Center for Disease Control recommends annual Chlamydia trachomatis screening for all sexually active females under 25 years old and additional testing for pregnant women and those with risk factors.

About cobas 4800 CT/NG testThe test runs on the fully automated cobas 4800 platform which was recently introduced in the US concurrent with the approval of Roche's HPV test.

The cobas CT/NG  test is a qualitative in-vitro test for the detection of CT/NG in patient specimens. The test utilizes amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of CT/NG in a single analysis. The test, CE marked in 2009, is currently available in numerous countries around the world.

The cobas 4800 System is designed to deliver new standards in laboratory testing efficiency and medically relevant diagnostic information.  

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.Roche Molecular SystemsPhone: 888-545-2443
'/>"/>

SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Reports Second Quarter Results
2. Rochester Medical Announces Second Quarter 2011 Earnings Conference Call Thursday, May 5, 2011
3. Roche Launches EMR Interface for VA to Facilitate Diabetes Management
4. Rochester Medical Completes Acquisition of Laprolan
5. MITs Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
6. Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
7. Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
8. Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
9. Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD
10. Rochester Medical Reports First Quarter Results and Recent Developments
11. Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , May 31, 2016 The ... is progressing at a CAGR of 10.6% within a ... valued at US$0.46 bn in 2013. Owing to favorable ... to reach US$0.88 bn by the end of this ... from the market,s holistic representation in a research report ...
(Date:5/31/2016)... ZIONA, Israel , May 31, ... medicine company utilizing its proprietary plant-based rhCollagen technology for ... authorization from the Chief Scientist of Israel,s ... of its NIS 12 million development project for 2016. The ... higher than last year,s authorized grant, which totaled NIS ...
(Date:5/30/2016)... India , May 30, 2016 /PRNewswire/ ... market research report "Healthcare Biometrics Market by ... (Signature, Voice)), Multifactor, Multimodal), Application (Workforce Management), ... Forecast to 2021", published by MarketsandMarkets, the ... Million by 2021 from USD 1,182.6 Million ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Twenty years ago it was revolutionary: ... trying to silence the voices they hear. But this approach has proven transformative, both ... method has steadily gained credibility and now is used around the world, but it ...
(Date:5/31/2016)... Eden Prairie, MN (PRWEB) , ... May 31, 2016 , ... ... accreditation from the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ... the most common means of achieving a leak-free connection between two medical devices (e.g. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service ... as a whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander ... presenting the opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO ...
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international leaders ... spa and beauty in Europe. The organization asked its partner experts in Europe - ... - to forecast where wellness is headed in Europe. Predictions range from European nations ...
(Date:5/31/2016)... Montana (PRWEB) , ... May 31, 2016 , ... Spectrum ... Lift. This new lift has been designed and built with the user in mind. ... of aquatic consultants have informed us that an ADA 400 lbs lift is a ...
Breaking Medicine News(10 mins):